Sugi Predict
/ Targets
/ BUB3
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to BUB3 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression |
PHASE3 | RECRUITING |
| Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer |
PHASE2 | UNKNOWN |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) |
PHASE1/PHASE2 | RECRUITING |
| Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma |
PHASE2 | COMPLETED |
| Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment |
PHASE2 | NOT_YET_RECRUITING |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects |
PHASE1/PHASE2 | COMPLETED |
| Abemaciclib With or Without Atezolizumab for mCRPC |
PHASE2 | COMPLETED |
| Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma |
PHASE2 | RECRUITING |
| Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma |
PHASE1/PHASE2 | COMPLETED |
| Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| INCB018424 in Patients With Advanced Hematologic Malignancies |
PHASE2 | COMPLETED |
| Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel |
PHASE1 | COMPLETED |
| Study of ABT-751 in Patients With Refractory Hematologic Malignancies |
PHASE1 | COMPLETED |
| Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| A Clinical Study of TQB3824 in Subjects With Advanced Cancer |
PHASE1 | UNKNOWN |
| AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors |
PHASE1 | COMPLETED |
| PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck |
PHASE1 | COMPLETED |
| Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia |
PHASE1 | WITHDRAWN |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Tamoxifen in Patients With Oesophageal Cancer |
PHASE1 | UNKNOWN |
| E7389 in Treating Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Importance of the Microtubule Cytoskeleton in Oocyte Competence |
nan | COMPLETED |
| Study of the Effect of Innate on the Inflammatory Response to Endotoxin |
nan | RECRUITING |
| Identification of Genetic Basis of Atrioventricular Conduction Defects: From Congenital Forms to Degenerative Forms |
nan | UNKNOWN |
| Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 |
nan | COMPLETED |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a BUB3 binder may also engage these)